Literature DB >> 18386138

Morphological alterations induced by doxorubicin on H9c2 myoblasts: nuclear, mitochondrial, and cytoskeletal targets.

Vilma A Sardão1, Paulo J Oliveira, Jon Holy, Catarina R Oliveira, Kendall B Wallace.   

Abstract

Doxorubicin (Dox) is a very potent antineoplastic agent used against several types of cancer, despite a cumulative cardiomyopathy that reduces the therapeutic index for treatment. H9c2 myoblast cells have been used as an in vitro model to study biochemical alterations induced by Dox treatment on cardiomyocyte cells. Despite the extensive work already published, few data are available regarding morphological alterations of H9c2 cells during Dox treatment. The purpose of the present work was to evaluate Dox-induced morphological alterations in H9c2 myoblasts, focusing especially on the nuclei, mitochondria, and structural fibrous proteins. Treatment of H9c2 cell with low concentrations of Dox causes alterations in fibrous structural proteins including the nuclear lamina and sarcomeric cardiac myosin, as well as mitochondrial depolarization and fragmentation, membrane blebbing with cell shape changes, and phosphatidylserine externalization. For higher Dox concentrations, more profound alterations are evident, including nuclear swelling with disruption of nuclear membrane structure, mitochondrial swelling, and extensive cytoplasm vacuolization. The results obtained indicate that Dox causes morphological alterations in mitochondrial, nuclear, and fibrous protein structures in H9c2 cells, which are dependent on the drug concentration. Data obtained with the present study allow for a better characterization of the effects of Dox on H9c2 myoblasts, used as a model to study Dox-induced cardiotoxicity. The results obtained also provide new and previously unknown targets that can contribute to understand the mechanisms involved in the cardiotoxicity of Dox.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18386138     DOI: 10.1007/s10565-008-9070-1

Source DB:  PubMed          Journal:  Cell Biol Toxicol        ISSN: 0742-2091            Impact factor:   6.691


  38 in total

1.  Pharmacokinetics, antitumor and cardioprotective effects of liposome-encapsulated phenylaminoethyl selenide in human prostate cancer rodent models.

Authors:  Jeong Yeon Kang; Mathew Eggert; Shravanthi Mouli; Ibrahim Aljuffali; Xiaoyu Fu; Ben Nie; Amy Sheil; Kendall Waddey; Charlie D Oldham; Sheldon W May; Rajesh Amin; Robert D Arnold
Journal:  Pharm Res       Date:  2014-08-27       Impact factor: 4.200

2.  Detecting the functional complexities between high-density lipoprotein mimetics.

Authors:  Yoshitaka J Sei; Jungho Ahn; Taeyoung Kim; Eunjung Shin; Angel J Santiago-Lopez; Seung Soon Jang; Noo Li Jeon; Young C Jang; YongTae Kim
Journal:  Biomaterials       Date:  2018-04-06       Impact factor: 12.479

3.  Irisin plays a pivotal role to protect the heart against ischemia and reperfusion injury.

Authors:  Hao Wang; Yu Tina Zhao; Shouyan Zhang; Patrycja M Dubielecka; Jianfeng Du; Naohiro Yano; Y Eugene Chin; Shougang Zhuang; Gangjian Qin; Ting C Zhao
Journal:  J Cell Physiol       Date:  2017-05-03       Impact factor: 6.384

4.  Mode of treatment governs curcumin response on doxorubicin-induced toxicity in cardiomyoblasts.

Authors:  Aditi Jain; Vibha Rani
Journal:  Mol Cell Biochem       Date:  2017-09-19       Impact factor: 3.396

5.  Membrane blebbing as an assessment of functional rescue of dysferlin-deficient human myotubes via nonsense suppression.

Authors:  Bingjing Wang; Zhaohui Yang; Becky K Brisson; Huisheng Feng; Zhiqian Zhang; Ellen M Welch; Stuart W Peltz; Elisabeth R Barton; Robert H Brown; H Lee Sweeney
Journal:  J Appl Physiol (1985)       Date:  2010-06-17

6.  ErbB2 overexpression upregulates antioxidant enzymes, reduces basal levels of reactive oxygen species, and protects against doxorubicin cardiotoxicity.

Authors:  Frances Belmonte; Samarjit Das; Polina Sysa-Shah; Vidhya Sivakumaran; Brian Stanley; Xin Guo; Nazareno Paolocci; Miguel A Aon; Masaki Nagane; Periannan Kuppusamy; Charles Steenbergen; Kathleen Gabrielson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-08-07       Impact factor: 4.733

Review 7.  Cardiac toxicity of anticancer agents.

Authors:  Alessandro Colombo; Carlo Cipolla; Marta Beggiato; Daniela Cardinale
Journal:  Curr Cardiol Rep       Date:  2013-05       Impact factor: 2.931

8.  Mitochondrionopathy phenotype in doxorubicin-treated Wistar rats depends on treatment protocol and is cardiac-specific.

Authors:  Gonçalo C Pereira; Susana P Pereira; Claudia V Pereira; José A Lumini; José Magalhães; António Ascensão; Maria S Santos; António J Moreno; Paulo J Oliveira
Journal:  PLoS One       Date:  2012-06-22       Impact factor: 3.240

9.  Doxorubicin Cytotoxicity in Differentiated H9c2 Cardiomyocytes: Evidence for Acute Mitochondrial Superoxide Generation.

Authors:  Muath Helal; Jane Alcorn; Brian Bandy
Journal:  Cardiovasc Toxicol       Date:  2020-09-10       Impact factor: 3.231

Review 10.  Noncoding RNAs in doxorubicin-induced cardiotoxicity and their potential as biomarkers and therapeutic targets.

Authors:  Hong-Ge Fa; Wen-Guang Chang; Xue-Juan Zhang; Dan-Dan Xiao; Jian-Xun Wang
Journal:  Acta Pharmacol Sin       Date:  2020-07-21       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.